Cargando…
Medication-induced hyperglycemia: pediatric perspective
Medication-induced hyperglycemia is a frequently encountered clinical problem in children. The intent of this review of medications that cause hyperglycemia and their mechanisms of action is to help guide clinicians in prevention, screening and management of pediatric drug-induced hyperglycemia. We...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954773/ https://www.ncbi.nlm.nih.gov/pubmed/31958298 http://dx.doi.org/10.1136/bmjdrc-2019-000801 |
_version_ | 1783486851048275968 |
---|---|
author | Tosur, Mustafa Viau-Colindres, Johanna Astudillo, Marcela Redondo, Maria Jose Lyons, Sarah K |
author_facet | Tosur, Mustafa Viau-Colindres, Johanna Astudillo, Marcela Redondo, Maria Jose Lyons, Sarah K |
author_sort | Tosur, Mustafa |
collection | PubMed |
description | Medication-induced hyperglycemia is a frequently encountered clinical problem in children. The intent of this review of medications that cause hyperglycemia and their mechanisms of action is to help guide clinicians in prevention, screening and management of pediatric drug-induced hyperglycemia. We conducted a thorough literature review in PubMed and Cochrane libraries from inception to July 2019. Although many pharmacotherapies that have been associated with hyperglycemia in adults are also used in children, pediatric-specific data on medication-induced hyperglycemia are scarce. The mechanisms of hyperglycemia may involve β cell destruction, decreased insulin secretion and/or sensitivity, and excessive glucose influx. While some medications (eg, glucocorticoids, L-asparaginase, tacrolimus) are markedly associated with high risk of hyperglycemia, the association is less clear in others (eg, clonidine, hormonal contraceptives, amiodarone). In addition to the drug and its dose, patient characteristics, such as obesity or family history of diabetes, affect a child’s risk of developing hyperglycemia. Identification of pediatric patients with increased risk of developing hyperglycemia, creating strategies for risk reduction, and treating hyperglycemia in a timely manner may improve patient outcomes. |
format | Online Article Text |
id | pubmed-6954773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-69547732020-01-23 Medication-induced hyperglycemia: pediatric perspective Tosur, Mustafa Viau-Colindres, Johanna Astudillo, Marcela Redondo, Maria Jose Lyons, Sarah K BMJ Open Diabetes Res Care Clinical Care/Education/Nutrition Medication-induced hyperglycemia is a frequently encountered clinical problem in children. The intent of this review of medications that cause hyperglycemia and their mechanisms of action is to help guide clinicians in prevention, screening and management of pediatric drug-induced hyperglycemia. We conducted a thorough literature review in PubMed and Cochrane libraries from inception to July 2019. Although many pharmacotherapies that have been associated with hyperglycemia in adults are also used in children, pediatric-specific data on medication-induced hyperglycemia are scarce. The mechanisms of hyperglycemia may involve β cell destruction, decreased insulin secretion and/or sensitivity, and excessive glucose influx. While some medications (eg, glucocorticoids, L-asparaginase, tacrolimus) are markedly associated with high risk of hyperglycemia, the association is less clear in others (eg, clonidine, hormonal contraceptives, amiodarone). In addition to the drug and its dose, patient characteristics, such as obesity or family history of diabetes, affect a child’s risk of developing hyperglycemia. Identification of pediatric patients with increased risk of developing hyperglycemia, creating strategies for risk reduction, and treating hyperglycemia in a timely manner may improve patient outcomes. BMJ Publishing Group 2020-01-08 /pmc/articles/PMC6954773/ /pubmed/31958298 http://dx.doi.org/10.1136/bmjdrc-2019-000801 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Clinical Care/Education/Nutrition Tosur, Mustafa Viau-Colindres, Johanna Astudillo, Marcela Redondo, Maria Jose Lyons, Sarah K Medication-induced hyperglycemia: pediatric perspective |
title | Medication-induced hyperglycemia: pediatric perspective |
title_full | Medication-induced hyperglycemia: pediatric perspective |
title_fullStr | Medication-induced hyperglycemia: pediatric perspective |
title_full_unstemmed | Medication-induced hyperglycemia: pediatric perspective |
title_short | Medication-induced hyperglycemia: pediatric perspective |
title_sort | medication-induced hyperglycemia: pediatric perspective |
topic | Clinical Care/Education/Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954773/ https://www.ncbi.nlm.nih.gov/pubmed/31958298 http://dx.doi.org/10.1136/bmjdrc-2019-000801 |
work_keys_str_mv | AT tosurmustafa medicationinducedhyperglycemiapediatricperspective AT viaucolindresjohanna medicationinducedhyperglycemiapediatricperspective AT astudillomarcela medicationinducedhyperglycemiapediatricperspective AT redondomariajose medicationinducedhyperglycemiapediatricperspective AT lyonssarahk medicationinducedhyperglycemiapediatricperspective |